Hi All,
I have few basic questions:
-
How would IPO of Biocon Biologics benefit existing shareholder ?
-
After demerging Syngene and Biocon Biologics would would remain with Biocon ? I mean what would be the revenue source ?
-
Would Biosimilar drug be able to take market share from existing players ? As in developed markets drugs are sold through prescription. Why would doctor jeopard his existing relationship with Innovator andIf innovator also drops price then ?
| Subscribe To Our Free Newsletter |
